2026年6月最新影响因子数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 热门AI工具： |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文摘要生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐： | 热 Wiley 2026暑期线上学习营 | 报名正式开启！ | 新 Springer Nature生物医学与生命科学资源合集 | 附免费书单 | 热 全流程投稿协助套餐服务 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Oncology Research and Treatment ONCOL RES TREAT （此期刊被最新的JCR期刊SCIE收录） LetPub评分 5.1
50人评分
我要评分
声誉 6.4 影响力 3.7 速度 7.0 | |||||||||||||||||||||||||
| 期刊ISSN | 2296-5270 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||||||
| E-ISSN | 2296-5262 | |||||||||||||||||||||||||
| 2025-2026最新IF （数据来源于网友提供） | 注册或登录后，查看IF | |||||||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：1.29 | |||||||||||||||||||||||||
| 2025-2026自引率 | 0.0%点击查看自引率趋势图 | |||||||||||||||||||||||||
| 五年IF （数据来源于网友提供） | 1.804数据由网友[rogue4021]收集提供 | |||||||||||||||||||||||||
| h-index | 43 | |||||||||||||||||||||||||
| CiteScore （ 2026年6月最新版） |
| |||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||
| 期刊官方网站 | http://www.karger.com/Journal/Home/224106 | |||||||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||||||
| 期刊投稿网址 | http://www.karger.com/Journal/Guidelines/224106 | |||||||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Apatinib Mesylate in the Treatment of Advanced Triple-Negative Breast Cancer Author: Huang, Xijia; Chen, Chao; Zeng, Hao; Wang, Lili; Chen, Mulan; Liu, Jian; Wu, Fan; Huang, Weiwei Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551064 Pirtobrutinib (pirto) vs ibrutinib (ibr) in treatment-naive (TN) and R/R relapsed/refractory CLL/SLL: Results from the fFirst randomized phase III study comparing a non-covalent (nc) and covalent BTK inhibitor (cBTKi) Author: Woyach, Jennifer; Qiu, Lugui; Grosicki, Sebastian; Wrobel, Tomasz; Capra, Marcelo; Czyz, Jaroslaw; Yi, Shuhua; Eom, Ki Seong; Panovska, Anna; Jurczak, Wojciech; Laribi, Kamel; Jacobasch, Lutz; Baker, Ross; Agajanian, Richy; Berkovits, Alejandro; Ozcan, Muhit; Marco, Jose Antonion Garcia; Lepretre, Stephane; Coombs, Catherine C.; Cramer, Paula; Lewis, Katherine L.; Hill, Marissa; Bao, Katherine; Bian, Yuanyuan; Stark, Amy S.; Leow, Ching Ching; Wierda, William Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 266-267. DOI: LUNAR-2: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer Author: Wehler, Thomas; Cobo, Manuel; Hayashi, Hidetoshi; Zhang, Li; Gray, Jhanelle; Hochmair, Maximilian; Langer, Corey; Schuette, Wolfgang Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 192-192. DOI: Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis Author: Van Cutsem, Eric; Xu, Jianming; Raymond, Eric; Hubner, Richard; Yoon, Harry H.; Kato, Ken; Wyrwicz, Lucjan; Tougeron, David; Park, Sook Ryun; Jimenez-Fonseca, Paula; Kojima, Takashi; Ishihara, Ryu; Avallone, Antonio; Pazo-Cid, Roberto; Xu, Sheng; Yan, Sebastian; Shi, Jingwen; Kong, Xuan; Lordick, Florian Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 207-208. DOI: | |||||||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Oncology Research and Treatment的语言要求，还能让Oncology Research and Treatment编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Oncology Research and Treatment编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||
| 通讯方式 | ALLSCHWILERSTRASSE 10, BASEL, SWITZERLAND, CH-4009 | |||||||||||||||||||||||||
| 出版商 | S. Karger AG | |||||||||||||||||||||||||
| 涉及的研究方向 | ONCOLOGY- | |||||||||||||||||||||||||
| 出版国家或地区 | GERMANY | |||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||||||
| 年文章数 | 67点击查看年文章数趋势图 | |||||||||||||||||||||||||
| Gold OA文章占比 | 16.22% | |||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 73.13% | |||||||||||||||||||||||||
| WOS期刊JCR分区 （ 2025-2026年最新版） | 注册或登录后，查看WOS分区等级 | |||||||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||
  | ||||||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2296-5270%5BISSN%5D | |||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： | |||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Oncology Research and Treatment顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Apatinib Mesylate in the Treatment of Advanced Triple-Negative Breast Cancer Author: Huang, Xijia; Chen, Chao; Zeng, Hao; Wang, Lili; Chen, Mulan; Liu, Jian; Wu, Fan; Huang, Weiwei Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551064 PubMed DOI |
| 2. | Pirtobrutinib (pirto) vs ibrutinib (ibr) in treatment-naive (TN) and R/R relapsed/refractory CLL/SLL: Results from the fFirst randomized phase III study comparing a non-covalent (nc) and covalent BTK inhibitor (cBTKi) Author: Woyach, Jennifer; Qiu, Lugui; Grosicki, Sebastian; Wrobel, Tomasz; Capra, Marcelo; Czyz, Jaroslaw; Yi, Shuhua; Eom, Ki Seong; Panovska, Anna; Jurczak, Wojciech; Laribi, Kamel; Jacobasch, Lutz; Baker, Ross; Agajanian, Richy; Berkovits, Alejandro; Ozcan, Muhit; Marco, Jose Antonion Garcia; Lepretre, Stephane; Coombs, Catherine C.; Cramer, Paula; Lewis, Katherine L.; Hill, Marissa; Bao, Katherine; Bian, Yuanyuan; Stark, Amy S.; Leow, Ching Ching; Wierda, William Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 266-267. DOI: |
| 3. | LUNAR-2: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer Author: Wehler, Thomas; Cobo, Manuel; Hayashi, Hidetoshi; Zhang, Li; Gray, Jhanelle; Hochmair, Maximilian; Langer, Corey; Schuette, Wolfgang Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 192-192. DOI: |
| 4. | Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis Author: Van Cutsem, Eric; Xu, Jianming; Raymond, Eric; Hubner, Richard; Yoon, Harry H.; Kato, Ken; Wyrwicz, Lucjan; Tougeron, David; Park, Sook Ryun; Jimenez-Fonseca, Paula; Kojima, Takashi; Ishihara, Ryu; Avallone, Antonio; Pazo-Cid, Roberto; Xu, Sheng; Yan, Sebastian; Shi, Jingwen; Kong, Xuan; Lordick, Florian Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 207-208. DOI: |
| 5. | Teclistamab Plus Daratumumab Versus Investigator's Choice of Daratumumab and Dexamethasone With Either Pomalidomide or Bortezomib (DPd/DVd) in Patients (Pts) With Relapsed Refractory Multiple Myeloma (RRMM): Results of the Phase 3 Randomized Study MajesTEC-3 Author: Teipel, Raphael; Mateos, Maria-Victoria; Bahlis, Nizar J.; Perrot, Aurore; Nooka, Ajay K.; Lu, Jin; Pawlyn, Charlotte; Mina, Roberto; Caeiro, Gaston; Kentos, Alain; Hungria, Vania; Reece, Donna; Niu, Ting; Mylin, Anne K.; Hansen, Charlotte Toftmann; Besemer, Britta; Dimopoulos, Meletios; Zamagni, Elena; Yoshihara, Satoshi; Kim, Kihyun; Min, Chang-Ki; Geerts, Paul; Van Leeuwen-Segarceanu, Elena; Tyczynska, Agata; Ortega, Juan Luis Reguera; Johansson, Magnus; Hansson, Markus; Turgut, Mehmet; Grey, Mark; Sidana, Surbhi; Rodriguez-Otero, Paula; Martinez-Lopez, Joaquin; Hashmi, Hamza; Carson, Robin; Kobos, Rachel; Sun, Weili; Lantz, Kristen; Seifert, Anne; Briseno-Toomey, Deborah; O'rourke, Lisa; Rubin, Maria; Vieyra, Diego; Kang, Lijuan; Costa, Luciano J Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 244-245. DOI: |
| 6. | PANOVA-3: Efficacy, safety and quality of life of Tumor Treating Fields ( TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC) Author: Seufferlein, Thomas; Picozzi, Vincent; Chandana, Sreenivasa R.; Melichar, Bohuslav; Kasi, Anup; Gang, Jin; Gallego Plazas, Javier; Bullock, Andrea J.; Hao, Chun-Yi; Wyrwicz, Lucjan; Hitre, Erika; Osipov, Arsen; de la Fouchardiere, Christelle; Ales, Inmaculada; Dragovich, Tomislav; Lee, Woo Jin; Feeney, Kynan; Philip, Philip; Ueno, Makoto; Van Cutsem, Eric; MacArulla Mercade, Teresa; Babiker, Hani Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 120-120. DOI: |
| 7. | Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (ABC): A Subgroup Analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients from EMBER-3 Author: Saura, Cristina; Carey, Lisa; Curigliano, Giuseppe; Harbeck, Nadia; O'shaughnessy, Joyce; Bidard, Francois-Clement; Casalnuovo, Monica Lis; Kim, Sung-Bae; Tokunaga, Eriko; Masuda, Norikazu; Watanabe, Junichiro; Wang, Xiaojia; Ouyang, Quchang; Ahn, Hee Kyung; Von Laue, Christoph Cramer; Cao, Shanshan; Knoderer, Holly; Jhaveri, Komal; Aftimos, Philippe; Fleischmann, Bastian; Fasching, Peter Andreas Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 54-54. DOI: |
| 8. | First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A Author: Quante, Michael; Zhou, Jian; Choi, Hye Jin; Ikeda, Masafumi; Lamarca, Angela; Oh, Do-Youn; Pressiani, Tiziana; Lim, Ho Yeong; Chon, Hong Jae; Kim, Hyung-Don; Casadei-Gardini, Andrea; Cheng, Ann-Lii; Xie, Ruifan; Xiang, Jinfeng; Miao, Rui; Aoli, Olivia; Muralidharan, Sujatha; Rahma, Osama E.; Kumar, Rakesh; Abou-Alf, Ghassan K Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 25-25. DOI: |
| 9. | Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK plus non-small cell lung cancer (NSCLC) Author: Muller-Huesmann, Harald; Dziadziuszko, Rafal; Solomon, Benjamin; Wu, Yi-Long; Ahn, Jin Seok; Nishio, Makoto; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wen-Zhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; de Marinis, Filippo; Migliorino, Maria Rita; Bondarenko, Igor; Xu, Tingting; Cardona, Andres; Scalori, Astrid; McNally, Virginia; Higgerson, Agata; Barlesi, Fabrice Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 290-291. DOI: |
| 10. | Recurrent patient-reported outcome (PRO)-based deterioration predicts overall survival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial Author: Moehler, Markus; Correa, Marcia Cruz; Oh, Do-Youn; Xu, Rui-Hua; Kato, Ken; Barzi, Afsaneh; Barnes, Bryant; Xu, Yaling; Sheng, Tao; Barnes, Gisoo; Victor, Timothy Journal: ONCOLOGY RESEARCH AND TREATMENT. 2026; Vol. 49, Issue , pp. 207-207. DOI: |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共34条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
